Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.60 |
| ▸ | MME | P08473 | 5/20 | 0.60 |
| ▸ | CPA1 | P15085 | 3/20 | 0.60 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.60 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.55 |
| ▸ | CHRNG | P07510 | 3/20 | 0.55 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.55 |
| ▸ | CHRND | Q07001 | 3/20 | 0.55 |
| ▸ | FCER2 | P06734 | 2/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18478933 | 1.00 | ACE (0.60) | ACEMMECPA1ACE2CHRNA1 | |
| SCHEMBL18478935 | 1.00 | ACE (0.60) | ACEMMECPA1ACE2CHRNA1 | |
| SCHEMBL30516543 | 0.95 | MME (0.65) | ACEMMECPA1ACE2FCER2 | |
| SCHEMBL25410995 | 0.95 | MME (0.65) | ACEMMECPA1ACE2FCER2 | |
| SCHEMBL25410999 | 0.95 | MME (0.65) | ACEMMECPA1ACE2FCER2 | |
| SCHEMBL25413002 | 0.95 | MME (0.65) | ACEMMECPA1ACE2FCER2 | |
| SCHEMBL4740393 | 0.90 | MME (0.63) | ACEMMECPA1ACE2FCER2 | |
| SCHEMBL30491086 | 0.90 | MME (0.63) | ACEMMECPA1ACE2FCER2 | |
| SCHEMBL4739434 | 0.90 | MME (0.63) | ACEMMECPA1ACE2FCER2 | |
| SCHEMBL30491089 | 0.90 | MME (0.63) | ACEMMECPA1ACE2FCER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155576-B2 | Synthetic peptides, enzymatic formation of pericellular hydrogels/nanofibrils, and methods of use | BRANDEIS UNIVERSITY (US) | 2021-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155576-B2 | Synthetic peptides, enzymatic formation of pericellular hydrogels/nanofibrils, and methods of use | DNPEP, ENPEP, ANPEP | ACE 863/4885MME 119/4885CPA1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.